Purespring Therapeutics’ UK Clinical Trial Application (CTA) for a planned Phase I/II study of PS-002 in patients with IgA nephropathy (IgAN) has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA), the NHS Health Research Authority (HRA) and Research Ethics Committee (REC). PS-002 was developed to target the underlying cause of many […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!